Nightingale Health’s blood analysis technology has been chosen from hundreds of applications to be presented at the Solve pitch event at United Nations headquarters in March. Solve is a program led by MIT seeking solutions for the world’s most challenging problems: refugee education, carbon emissions and in this case, chronic diseases.
Nightingale Health is a pioneering healthcare company. Their unique solution was chosen as one of 15 finalists in the chronic diseases challenge. Nightingale’s revolutionary technology provides detailed biological data from a single blood sample. This biological data helps to predict and prevent possible future chronic diseases such as cardiovascular conditions and diabetes. This affordable early risk prediction technology aims to enable people to reshape their future health. So rather than just diagnosing and treating diseases, we will be able to take preventive actions. The technology has been proven to advance research in chronic diseases and is supported by over 100 peer-reviewed biomedical publications. With its proprietary blood analysis technology, Nightingale believes that better healthcare should be for everyone and has developed its unique solution with affordability, clinical integration and scalability as core foundations. The clinical launch of Nightingale’s technology will begin in 2017 in Europe.
Solve will take place on March 7, 2017 at the headquarters of the United Nations in New York. Before the event, the public has an opportunity to vote for the solutions. Public votes will be taken into account when during the event an international panel of health care professionals will award the highly respected “Solvers” title to the most advanced solutions. Those chosen companies will then continue to develop solutions together with leading experts from MIT held in the Solve event in Massachusetts in May. Nightingale are excited to be chosen as one of the shortlisted companies.
Teemu Suna, Nightingale Health CEO explained his vision for the future:
“We believe everyone should be able to make life defining choices. With our new blood testing technology, we are liberating access to revolutionary affordable health data so that in the future we are no longer just told and diagnosed, we can predict our health. The Solve program is an inspiring movement and we are very proud to have been invited to join this illustrious group of forward thinking global innovators.”
Further information:
Teemu Suna, CEO, Co-founder
teemu.suna@nightingalehealth.com
+358 40 196 1669
Solve challenge voting until March 7th:
https://solvecolab.mit.edu/challenges/2016/cure-chronic-diseases
Solve at the United Nations -event:
http://solve.mit.edu/events/solve-at-the-united-nations
Solve MIT program:
http://solve.mit.edu/
Nightingale Health Ltd.
Nightingale Health (formerly known as Brainshake) is a pioneering healthcare company aiming to solve the world’s biggest health problem with its unique, proprietary and powerful blood testing re-invention. The technology has been proven to advance scientific research in chronic diseases and is supported by over 100 peer-reviewed biomedical publications. Early prediction and prevention of heart disease and diabetes is at the core of the technology. Nightingale’s mission is to make life defining choices possible, so that in the future we are no longer just told and diagnosed, we can predict our health.
